Copyright
©The Author(s) 2015.
World J Gastroenterol. Jun 21, 2015; 21(23): 7281-7288
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281
Figure 2 Kaplan-Meier plot of overall survival.
Median OS = 23.2 mo (95%CI: 20.1-27.2).
- Citation: Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288
- URL: https://www.wjgnet.com/1007-9327/full/v21/i23/7281.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i23.7281